Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Glucocorticoid-regulated genes in eosinophilic esophagitis: a role for FKBP51.

Caldwell JM, Blanchard C, Collins MH, Putnam PE, Kaul A, Aceves SS, Bouska CA, Rothenberg ME.

J Allergy Clin Immunol. 2010 Apr;125(4):879-888.e8. doi: 10.1016/j.jaci.2010.01.038.

2.

A randomized, double-blind, placebo-controlled trial of fluticasone propionate for pediatric eosinophilic esophagitis.

Konikoff MR, Noel RJ, Blanchard C, Kirby C, Jameson SC, Buckmeier BK, Akers R, Cohen MB, Collins MH, Assa'ad AH, Aceves SS, Putnam PE, Rothenberg ME.

Gastroenterology. 2006 Nov;131(5):1381-91.

PMID:
17101314
3.

IL-13 involvement in eosinophilic esophagitis: transcriptome analysis and reversibility with glucocorticoids.

Blanchard C, Mingler MK, Vicario M, Abonia JP, Wu YY, Lu TX, Collins MH, Putnam PE, Wells SI, Rothenberg ME.

J Allergy Clin Immunol. 2007 Dec;120(6):1292-300.

PMID:
18073124
4.

Treatment with topical steroids downregulates IL-5, eotaxin-1/CCL11, and eotaxin-3/CCL26 gene expression in eosinophilic esophagitis.

Lucendo AJ, De Rezende L, Comas C, Caballero T, Bellón T.

Am J Gastroenterol. 2008 Sep;103(9):2184-93. doi: 10.1111/j.1572-0241.2008.01937.x.

PMID:
18844613
5.

Efficacy, dose reduction, and resistance to high-dose fluticasone in patients with eosinophilic esophagitis.

Butz BK, Wen T, Gleich GJ, Furuta GT, Spergel J, King E, Kramer RE, Collins MH, Stucke E, Mangeot C, Jackson WD, O'Gorman M, Abonia JP, Pentiuk S, Putnam PE, Rothenberg ME.

Gastroenterology. 2014 Aug;147(2):324-33.e5. doi: 10.1053/j.gastro.2014.04.019.

6.

Involvement of mast cells in eosinophilic esophagitis.

Abonia JP, Blanchard C, Butz BB, Rainey HF, Collins MH, Stringer K, Putnam PE, Rothenberg ME.

J Allergy Clin Immunol. 2010 Jul;126(1):140-9. doi: 10.1016/j.jaci.2010.04.009.

7.

Clinical and immunopathologic effects of swallowed fluticasone for eosinophilic esophagitis.

Noel RJ, Putnam PE, Collins MH, Assa'ad AH, Guajardo JR, Jameson SC, Rothenberg ME.

Clin Gastroenterol Hepatol. 2004 Jul;2(7):568-75.

PMID:
15224281
8.

Eosinophilic esophagitis in children: immunopathological analysis and response to fluticasone propionate.

Teitelbaum JE, Fox VL, Twarog FJ, Nurko S, Antonioli D, Gleich G, Badizadegan K, Furuta GT.

Gastroenterology. 2002 May;122(5):1216-25.

PMID:
11984507
9.

Coordinate interaction between IL-13 and epithelial differentiation cluster genes in eosinophilic esophagitis.

Blanchard C, Stucke EM, Burwinkel K, Caldwell JM, Collins MH, Ahrens A, Buckmeier BK, Jameson SC, Greenberg A, Kaul A, Franciosi JP, Kushner JP, Martin LJ, Putnam PE, Abonia JP, Wells SI, Rothenberg ME.

J Immunol. 2010 Apr 1;184(7):4033-41. doi: 10.4049/jimmunol.0903069.

10.

Treatment with high-dose proton pump inhibitors helps distinguish eosinophilic esophagitis from noneosinophilic esophagitis.

Sayej WN, Patel R, Baker RD, Tron E, Baker SS.

J Pediatr Gastroenterol Nutr. 2009 Oct;49(4):393-9. doi: 10.1097/MPG.0b013e31819c4b3e.

PMID:
19633574
11.
12.

Induction of FKBP51 by aldosterone in intestinal epithelium.

Petrovich E, Asher C, Garty H.

J Steroid Biochem Mol Biol. 2014 Jan;139:78-87. doi: 10.1016/j.jsbmb.2013.10.006.

PMID:
24139875
13.

Glucocorticoids modulate NF-kappaB-dependent gene expression by up-regulating FKBP51 expression in Newcastle disease virus-infected chickens.

Park J, Kim M, Na G, Jeon I, Kwon YK, Kim JH, Youn H, Koo Y.

Mol Cell Endocrinol. 2007 Nov 15;278(1-2):7-17.

PMID:
17870233
14.

IL-13 induces esophageal remodeling and gene expression by an eosinophil-independent, IL-13R alpha 2-inhibited pathway.

Zuo L, Fulkerson PC, Finkelman FD, Mingler M, Fischetti CA, Blanchard C, Rothenberg ME.

J Immunol. 2010 Jul 1;185(1):660-9. doi: 10.4049/jimmunol.1000471.

15.

Inhibition of VCAM-1 expression in human bronchial epithelial cells by glucocorticoids.

Atsuta J, Plitt J, Bochner BS, Schleimer RP.

Am J Respir Cell Mol Biol. 1999 Apr;20(4):643-50.

PMID:
10100995
16.

Comparison of esomeprazole to aerosolized, swallowed fluticasone for eosinophilic esophagitis.

Peterson KA, Thomas KL, Hilden K, Emerson LL, Wills JC, Fang JC.

Dig Dis Sci. 2010 May;55(5):1313-9. doi: 10.1007/s10620-009-0859-4.

PMID:
19533356
17.

Resolution of remodeling in eosinophilic esophagitis correlates with epithelial response to topical corticosteroids.

Aceves SS, Newbury RO, Chen D, Mueller J, Dohil R, Hoffman H, Bastian JF, Broide DH.

Allergy. 2010 Jan;65(1):109-16. doi: 10.1111/j.1398-9995.2009.02142.x.

18.

FK506-binding protein 51 regulates nuclear transport of the glucocorticoid receptor beta and glucocorticoid responsiveness.

Zhang X, Clark AF, Yorio T.

Invest Ophthalmol Vis Sci. 2008 Mar;49(3):1037-47. doi: 10.1167/iovs.07-1279.

19.

Glucocorticoid-induced increase in lymphocytic FKBP51 messenger ribonucleic acid expression: a potential marker for glucocorticoid sensitivity, potency, and bioavailability.

Vermeer H, Hendriks-Stegeman BI, van der Burg B, van Buul-Offers SC, Jansen M.

J Clin Endocrinol Metab. 2003 Jan;88(1):277-84.

PMID:
12519866
20.

3-yr-follow-up of topical corticosteroid treatment for eosinophilic esophagitis in adults.

Helou EF, Simonson J, Arora AS.

Am J Gastroenterol. 2008 Sep;103(9):2194-9. doi: 10.1111/j.1572-0241.2008.01989.x. Erratum in: Am J Gastroenterol. 2010 Oct;105(10):2308.

PMID:
18637093
Items per page

Supplemental Content

Support Center